JL, M., J, M., LA, F., G, B., J, M. M., M, Q., . . . P, C. (2023). Adjuvant dabrafenib and trametinib for patients with resected <i>BRAF</i>-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
Citación estilo ChicagoJL, Manzano, et al. Adjuvant Dabrafenib and Trametinib for Patients With Resected <i>BRAF</i>-mutated Melanoma: DESCRIBE-AD Real-world Retrospective Observational Study. 2023.
Cita MLAJL, Manzano, et al. Adjuvant Dabrafenib and Trametinib for Patients With Resected <i>BRAF</i>-mutated Melanoma: DESCRIBE-AD Real-world Retrospective Observational Study. 2023.
Precaución: Estas citas no son 100% exactas.